Skip to main content
Figure 2 | World Journal of Surgical Oncology

Figure 2

From: A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer

Figure 2

(A) Kaplan-Meier DFS, median DFS time was 18 months (95% cumulative survival 0.6 to 35.4 months), the DFS rate at one, two, and three years was 54%, 47%, and 33%, respectively (left panel). Kaplan-Meier OS, median OS time was not reached, the OS rate at one, two, and three years was 73%, 69%, and 59%, respectively (right panel). (B) DFS differences in cN2 (left panel) and clinical response (right panel) after adjustment for other factors.

Back to article page